Decreased expression of SFXNs in renal tissues of mouse models of acute and chronic kidney disease

doi:10.16352/j.issn.1001-6325.2025.12.1541

Abstract

Abstract: Objective To investigate the expression changes of iron autophagy-mitochondrial ferric ion transport protein families (SFXNs) in acute kidney injury (AKI) and chronic kidney disease (CKD) mouse models induced by cisplatin (Cis) and ischemia reperfusion (IR). Methods C57BL/6 mice were randomly divided into control group (control), Cis-AKI group, Cis-CKD group, sham-operated group (sham), IR-AKI group, and IR-CKD group. Serum and kidney tissue samples were collected from mice. Serum creatinine (Cr) and blood urea nitrogen (BUN) levels were detected. Pathological changes in renal tissues were observed by HE staining. Western blot was used to detect the expression of renal SFXNs and kidney injury related proteins. Results Compared with the control or sham group, the levels of BUN and Cr in the serum of the model group were significantly increased(P＜0.05), the renal tissue showed significant pathological damage, with the kidney injury molecule-1(KIM-1), neutrophil gelatinase-associated lipocalin(NGAL), and pro-apoptotic protein Bax significantly upregulated(P＜0.05), while the anti-apoptotic protein Bcl-2 was significantly downregulated (P＜0.05). Compared to the control or sham group, the Cis-AKI group showed a significant downregulation of SFXN4 (P＜0.05); The SFXN4 and SFXN5 subtypes were significantly downregulated in the IR-AKI group and Cis-CKD group (P＜0.05); All five subtypes of SFXN in the IR-CKD group were significantly downregulated (P＜0.05). Conclusions Cis or IR induces renal tissue damage and tubular mitochondrial injury in mice and affects the expression of SFXN family proteins, suggesting their potential role in renal injury of animal models.

Key words: cisplatin, ischemia reperfusion, acute kidney injury, chronic kidney disease, sideroflexins

CLC Number:

R363

GAO Li, WANG Siyi, ZHANG Minjing, ZHAO Lin, XU Zheming, ZHANG Gensheng, YAN Jieping. Decreased expression of SFXNs in renal tissues of mouse models of acute and chronic kidney disease[J]. Basic & Clinical Medicine, 2025, 45(12): 1541-1547.

References

[1] Liu Kaixuan, Hao Xiaoyu, Gao Yangfan, et al. CUL4B protects kidneys from acute injury by restraining p53/PAI-1 signaling[J]. Cell Death Dis, 2024, 15:915. doi: 10.1038/s41419-024-07299-w.
[2] 张欣, 廖晓辉. 线粒体功能障碍在急性肾损伤向慢性肾脏疾病转变中的作用[J]. 基础医学与临床, 2021, 41: 589-592.
[3] 何也川, 王丹玲. SFXN 家族蛋白的功能及其在疾病中作用的研究进展[J]. 中南医学科学杂志, 2024, 52: 157-162.
[4] Jackson TD, Hock DH, Fujihara KM, et al. The TIM22 complex mediates the import of sideroflexins and is required for efficient mitochondrial one-carbon metabolism[J]. Mol Biol Cell, 2021, 32: 475-491.
[5] Xu Z, Zhang M, Wang W, et al. Dihydromyricetin attenuates cisplatin-induced acute kidney injury by reducing oxidative stress, inflammation and ferroptosis[J]. Toxicol Appl Pharmacol, 2023, 473:116595.doi: 10.1016/j.taap.2023.116595.
[6] Li S, Livingston MJ, Ma Z, et al. Tubular cell senescence promotes maladaptive kidney repair and chronic kidney disease after cisplatin nephrotoxicity[J]. JCI Insight, 2023, 8: e166643.doi: 10.1172/jci.insight.166643.
[7] Fu Y, Xiang Y, Wei Q, et al. Rodent models of AKI and AKI-CKD transition: an update in 2024[J]. Am J Physiol Renal Physiol, 2024, 326: F563-F583.
[8] See EJ, Jayasinghe K, Glassford N, et al. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure[J]. Kidney Int, 2019, 95:160-172.
[9] Chang LY, Chao YL, Chiu CC, et al. Mitochondrial signaling, the mechanisms of AKI-to-CKD transition and potential treatment targets[J]. Int J Mol Sci, 2024, 25:1518.doi: 10.3390/ijms25031518.
[10] Zhang L, Miao M, Xu X, et al. From physiology to pathology: the role of mitochondria in acute kidney injuries and chronic kidney diseases[J]. Kidney Dis (Basel), 2023, 9:342-357.
[11] Kory N, Wyant GA, Prakash G, et al. SFXN1 is a mitochondrial serine transporter required for one-carbon metabolism[J]. Science, 2018; 362: eaat9528.doi: 10.3390/ijms25031518.
[12] Andriani L, Ling YX, Yang SY, et al. Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting TOLLIP-mediated autophagic degradation of CIP2A[J]. Cancer Lett, 2024, 597:217008.doi: 10.1016/j.canlet.2024.217008.
[13] Ledahawsky LM, Terzenidou ME, Edwards R, et al. The mitochondrial protein Sideroflexin 3 (SFXN3) influences neurodegeneration pathways in vivo[J]. FEBS J, 2022, 289:3894-3914.
[14] Tesfay L, Paul BT, Hegde P, et al. Complementary anti-cancer pathways triggered by inhibition of sideroflexin 4 in ovarian cancer[J]. Sci Rep, 2022, 12:19936.doi: 10.1038/s41598-022-24391-3.
[15] Chen Y, Qian J, Ding P, et al. Elevated SFXN2 limits mitochondrial autophagy and increases iron-mediated energy production to promote multiple myeloma cell proliferation[J]. Cell Death Dis, 2022, 13:822.doi: 10.1038/s41419-022-05272-z